fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Conjugated estrogens

All products: general benefit

Premarin Vaginal Cream · DIN 02043440 · 0.625 mg/g · Vag Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Premarin Vaginal Cream · DIN 02043440 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-06-19 · brand PREMARIN VAGINAL CREAM · ATC G03CA57 CONJUGATED ESTROGENS · form Cream · route Vaginal · ingredients CONJUGATED ESTROGENS 0.625 MG/G · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Premarin Vaginal Cream: Formulary list price $0.93 per unit (the source does not state the unit; exact figure $0.9283). What the ministry pays, not the patient.

Ministry pays: $0.9283 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02043440)

Source record
DIN 02043440: Premarin Vaginal Cream Raw flags: sec3=Y Item: 681600007; group id 732; item number 1796; lccId None; manufacturer id PFI Source form: Vag Cr; strength: 0.625mg/g Recorded listing: General benefit Source prices (unrounded): $0.9283; ministry $0.9283 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02043440 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15704
Shortage status: active shortage (reported June 30, 2026, last updated August 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02043440
Shortage record checked October 6, 2026

Other products in the same Health Canada class (G03CA): coverage varies; not interchangeable

  • Estradiol (Estrace): general benefit, not a benefit
  • B + estradiol (Vagifem 10): general benefit
  • Estradiol hemihydrate (Imvexxy): general benefit
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered

Matched class: 68:16 Estrogens

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE Some products covered without a code (check the product listing): ESTRADIOL 68:16 Estrogens

ESTRADIOL

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 0.5mg, 1mg, 2mg · Tab, Vag Ring

ESTRADIOL 17-B

· 1 products · General benefit · strengths: 10mcg · Vag Tab with Applicator

ESTRADIOL HEMIHYDRATE

· 2 products · General benefit · strengths: 4mcg, 10mcg · Vag Insert

ESTRADIOL HEMIHYDRATE & PROGESTERONE

· 1 products · General benefit · strengths: 1mg & 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:16
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Premarin® Vaginal Cream is indicated in the treatment of atrophic vaginitis, dyspareunia, and kraurosis vulvae. PREMARIN® VAGINAL CREAM HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS. Premarin® Vaginal Cream should be prescribed with an appropriate dose of a progestin for women with intact uteri in order to prevent endometrial hyperplasia/carcinoma Geriatrics (> 65 years of age): See above indications. Pediatrics (< 16 years of age): Premarin® Vaginal Cream is not indicated for use in children. https://pdf.hres.ca/dpd_pm/00081174.PDF PM date: JUN 26, 2025 Source product: PREMARIN VAGINAL CREAM; DIN 02043440; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Premarin Vaginal Cream · DIN 02043440 Shortage status: active shortage (reported 2026-06-30, last updated 2026-08-18); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02043440

Check this DIN again